Ocular Therapeutix, Inc. (OCUL)Healthcare | Biotechnology | Bedford, United States | NasdaqGM
7.24 USD
-0.32
(-4.233%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 3:22 a.m. EDT
The investment case for Ocular Therapeutix is currently defined by a stark disconnect between its deteriorating financial reality and its speculative upside potential. Fundamentally, the company is trapped in a value trap: it is burning significant cash with negative operating margins, generating no free cash flow, and showing negligible revenue growth. The balance sheet, while currently liquid, is not generating organic fuel for growth, and the stock has suffered a brutal multi-year decline where the market has repeatedly punished the business quality. Despite a 'strong buy' analyst consensus driven by a distant target price, the underlying economics do not support a high-conviction long-term hold. However, the short-term outlook is being propped up by a massive catalyst event regarding the AXPAXLI trial for wet AMD. This clinical progress has reignited hope for a turnaround, which is why the options market is aggressively pricing in a move higher, with heavy call open interest at $10 and beyond. The recent price action, which has been volatile and trending lower despite the news, suggests the market is still skeptical of the immediate impact. While the long-term fundamentals remain weak due to the lack of profitability and growth, the specific catalyst creates a temporary window of opportunity where the stock could decouple from its poor earnings profile. Investors should view this as a high-risk, event-driven trade rather than a traditional buy-and-hold opportunity. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.160913 |
| MSTL | 0.162636 |
| AutoETS | 0.164388 |
| AutoARIMA | 0.164389 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 4.46 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.112 |
| Excess Kurtosis | -0.45 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 15.265 |
| Revenue per Share | 0.243 |
| Market Cap | 1,590,018,816 |
| Forward P/E | -4.89 |
| Beta | 0.99 |
| Website | https://www.ocutx.com |
As of Oct. 10, 2026, 3:22 a.m. EDT: Options activity shows a distinct bullish bias with heavy open interest in out-of-the-money calls (OTM OI % consistently above 90%) compared to puts. Significant call positioning exists at strikes of $10, $12, and $20, suggesting speculation on a recovery toward the $10 level or higher. Put volume is concentrated near the money ($7-$8), indicating defensive hedging rather than a bearish bet on further collapse. Implied volatility remains elevated relative to deep ITM strikes, reflecting uncertainty around the upcoming catalysts.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.3268032 |
| Address1 | 14 Crosby Drive |
| Address2 | 3rd Floor |
| All Time High | 44.19 |
| All Time Low | 1.995 |
| Ask | 10.89 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 4,087,430 |
| Average Daily Volume3 Month | 2,849,193 |
| Average Volume | 2,849,193 |
| Average Volume10Days | 4,087,430 |
| Beta | 0.992 |
| Bid | 6.26 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 2.368 |
| City | Bedford |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 7.24 |
| Current Ratio | 13.105 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 7.61 |
| Day Low | 7.205 |
| Debt To Equity | 15.265 |
| Display Name | Ocular Therapeutix |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,777,982,400 |
| Earnings Call Timestamp Start | 1,777,982,400 |
| Earnings Timestamp | 1,785,760,200 |
| Earnings Timestamp End | 1,793,795,400 |
| Earnings Timestamp Start | 1,793,795,400 |
| Ebitda | -308,457,984 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -3.471 |
| Enterprise To Revenue | 20.57 |
| Enterprise Value | 1,070,760,896 |
| Eps Current Year | -1.44415 |
| Eps Forward | -1.48031 |
| Eps Trailing Twelve Months | -1.4 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 9.6379 |
| Fifty Day Average Change | -2.3979006 |
| Fifty Day Average Change Percent | -0.24879907 |
| Fifty Two Week Change Percent | -32.68032 |
| Fifty Two Week High | 16.44 |
| Fifty Two Week High Change | -9.200001 |
| Fifty Two Week High Change Percent | -0.5596107 |
| Fifty Two Week Low | 6.23 |
| Fifty Two Week Low Change | 1.0099998 |
| Fifty Two Week Low Change Percent | 0.16211873 |
| Fifty Two Week Range | 6.23 - 16.44 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,406,295,000,000 |
| Float Shares | 184,714,514 |
| Forward Eps | -1.48031 |
| Forward P E | -4.890867 |
| Free Cashflow | -159,248,992 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 325 |
| Fullday Change | 0.09000015 |
| Fullday Change Percent | 1.2430961 |
| Fullday Price | 7.33 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Gross Profits | -178,162,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.009190001 |
| Held Percent Institutions | 0.95263 |
| Implied Shares Outstanding | 219,615,868 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts. |
| Long Name | Ocular Therapeutix, Inc. |
| Market | us_market |
| Market Cap | 1,590,018,816 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_41955650 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -301,447,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,196,158,680 |
| Number Of Analyst Opinions | 12 |
| Open | 7.505 |
| Operating Cashflow | -238,239,008 |
| Operating Margins | -6.09343 |
| Overall Risk | 9 |
| Phone | 781 357 4000 |
| Pre Market Change | 0.09000015 |
| Pre Market Change Percent | 1.2430961 |
| Pre Market Price | 7.33 |
| Pre Market Time | 1,791,976,445 |
| Previous Close | 7.56 |
| Price Eps Current Year | -5.0133295 |
| Price Hint | 2 |
| Price To Book | 3.0574324 |
| Price To Sales Trailing12 Months | 30.544977 |
| Profit Margins | 0.0 |
| Quick Ratio | 12.789 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | -0.32 |
| Regular Market Change Percent | -4.23281 |
| Regular Market Day High | 7.61 |
| Regular Market Day Low | 7.205 |
| Regular Market Day Range | 7.205 - 7.61 |
| Regular Market Open | 7.505 |
| Regular Market Previous Close | 7.56 |
| Regular Market Price | 7.24 |
| Regular Market Time | 1,791,921,600 |
| Regular Market Volume | 3,214,238 |
| Return On Assets | -0.34952 |
| Return On Equity | -0.72993 |
| Revenue Growth | 0.001 |
| Revenue Per Share | 0.243 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 7 |
| Shares Outstanding | 219,615,868 |
| Shares Percent Shares Out | 0.1339 |
| Shares Short | 29,412,673 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 28,055,522 |
| Short Name | Ocular Therapeutix, Inc. |
| Short Percent Of Float | 0.15810001 |
| Short Ratio | 9.49 |
| Source Interval | 15 |
| State | MA |
| Symbol | OCUL |
| Target High Price | 34.0 |
| Target Low Price | 14.0 |
| Target Mean Price | 26.0 |
| Target Median Price | 27.5 |
| Total Cash | 598,641,024 |
| Total Cash Per Share | 2.726 |
| Total Debt | 79,383,000 |
| Total Revenue | 52,055,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.4 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 9.45195 |
| Two Hundred Day Average Change | -2.2119503 |
| Two Hundred Day Average Change Percent | -0.23402052 |
| Type Disp | Equity |
| Volume | 3,214,238 |
| Website | https://www.ocutx.com |
| Zip | 1,730 |